Switch View
© Globe Newswire
22.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
News Preview
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
News Preview
PARIS, FRANCE, 22 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. Patients treated with IPN10200 showed a statistically significant improvement in response at Week 4 vs plac...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CH0363463438
Idorsia Ltd
IDIA
LISTED
SIX
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
News Preview
Allschwil, Switzerland – September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ, Idorsia’s dual orexin receptor antagonist, is indicated for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
22.09.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
News Preview
Basel, 22 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA study evaluating investigational giredestrant in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer p...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
22.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
News Preview
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
News Preview
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: KYG0520K1094
Ascletis Pharma Inc.
1672
LISTED
HKSE
Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
News Preview
- The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide group compared to 57.1% in the semaglutide monotherapy group.
- Ultra-long-...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: CNE100003F19
Wuxi Apptec Co., Ltd.
2359
LISTED
HKSE
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
News Preview
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US84763A1088
Spectrum Pharmaceuticals, Inc.
SPPI
LISTED
NASDAQ
SPPI Deadline: Rosen Law Firm Urges Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”). The lead plaintiff process was reopened by the Court. S...
Themefolio
Profiler
Peergroup
© BusinessWire
21.09.2025
ISIN: US8753722037
Tandem Diabetes Care Inc
TNDM
LISTED
NASDAQ
TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. (“Tandem” or “the Company”) (NASDAQ: TNDM) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or fail...
Themefolio
Profiler
Peergroup
© BusinessWire
21.09.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Themefolio
Profiler
Peergroup
© PR Newswire
21.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 21, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates i...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
21.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 21, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Cla...
Themefolio
Profiler
Peergroup
© PR Newswire
21.09.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 21, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2025
ISIN: IL0006290147
Teva Pharmaceutical Industries Ltd
TEVA
LISTED
TLV
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUSTEDO XR rep...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2025
ISIN: IL0006290147
Teva Pharmaceutical Industries Ltd
TEVA
LISTED
TLV
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
News Preview
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of 10 posters from its innovative schizophrenia medicines portfolio, including long-term safety data from the completed SOLARIS Phase 3 tri...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”). Jasper is a clinical-stage biotechnology company.
For more information...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL
News Preview
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
So what: If yo...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman
News Preview
REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline
SAN FRANCISCO, Sept. 20, 2025 On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2025
ISIN: CA68237C1059
Onco-Innovations Limited
ONCO
LISTED
CSE
Steht die Aktie vor einer Neubewertung? Nanopartikel-Meilenstein ebnet Weg zu präklinischen Studien
News Preview
EQS-Media / 20.09.2025 / 15:40 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass “Dalton Pharma Services” (“Dalton”) seine Aktivitäten zur Herstellung der proprietären Nanopartikelformulierung von Onco, auch als “PEO-b-PBz-CL” Poly(ethylenoxid)-Block-Poly(-benzylcarb......
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
RXST Deadline: RXST Investors with Losses in Excess of $100K Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 20, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025, both dates inclusive (the "Clas...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2025
ISIN: US12529R1077
C4 Therapeutics Inc
CCCC
LISTED
NASDAQ
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
News Preview
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US4718711033
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
Do you own shares of KBR? Robbins LLP Informs Investors of the Jasper Therapeutics, Inc. Class Action Lawsuit
News Preview
SAN DIEGO, Sept. 20, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology company, focuses on developing therap...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2025
ISIN: CA68237C1059
Onco-Innovations Limited
ONCO
LISTED
CSE
Onco-Innovations beginnt gemeinsam mit “Dalton Pharma” mit der Herstellung von Nanopartikelformulierungen für präklinische Tierstudien
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass “Dalton Pharma Services” (“Dalton”) seine Aktivitäten zur Herstellung der proprietären Nanopartikelformulierung von Onco, auch als “PEO-b-PBz-CL” Poly(ethylenoxid)-Block-Poly(-benzylcarboxylat -caprolacton) bezeichnet, begonnen hat......
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Did you lose money in LNTH? Shareholders Who Incurred Significant Losses in Lantheus Holdings, Inc. Should Contact Robbins LLP for Information
News Preview
SAN DIEGO, Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc. (NASAQ: LNTH) securities between February 26, 2025 and August 5, 2025. Lantheus is a global company that develops, manufactures, sells, and distribu...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit
News Preview
SAN DIEGO, Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience, Inc. (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering ("IPO") conduc...
Themefolio
Profiler
Peergroup
© Newsfile
20.09.2025
ISIN: CA74141E1043
PreveCeutical Medical Inc.
PREV
LISTED
CSE
PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its News Release of September 4, 2025, it has filed with the applicable Canadian securities regulatory authorities the management information ci...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidas...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
News Preview
TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease
TREMFYA® achieved significant rates of clinical remission and endoscopic improvement versus placebo at Week 12 with a subcutaneous induction regimen, consistent with IV induction
Johnson...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: CA23344H1091
DRI Healthcare Trust
DHT.U
LISTED
TSX
DRI Healthcare Trust Promotes Zaheed Mawani to Chief Financial Officer
News Preview
TORONTO, Sept. 19, 2025 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") is pleased to announce the promotion of Zaheed Mawani to Chief Financial Officer, effective October 1, 2025.
Mr. Mawani joined DRI H...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US42226B2043
National Healthcare Properties Inc 7.375%
NHPAP
LISTED
NASDAQ
National Healthcare Properties Announces Preferred Stock Dividends
News Preview
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) (“NHP”) announced today that it declared quarterly dividends on its outstanding preferred stock. Specifically, NHP declared a dividend of $0.4609375 per share on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock payable on O...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US74754R1032
Qualigen Therapeutics, Inc.
QLGN
LISTED
NASDAQ
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction
News Preview
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company, and Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("QLGN"), jointly announced that they have entered into a securi...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US1266501006
CVS Health Corp
CVS
LISTED
NYSE
CVS Pharmacy celebrates reopening of Pacific Palisades store damaged by devastating wildfires
News Preview
The Swarthmore Avenue CVS Pharmacy is the first community pharmacy to reopen in the neighborhood, increasing access to health and wellness essentials
WOONSOCKET, R.I., Sept. 19, 2025 /PRNewswire/ -- Today, leaders from CVS Health® (NYSE: CVS) were joined by state and local representatives to celebrate the recently reopened Pacific Palisades CVS P...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: CA98421R1055
XPhyto Therapeutics Corp.
XPHY
LISTED
CSE
BioNxt Solutions Announces Closing of Shares for Debt Settlement
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of September 12, 2025, it has closed its debt settlement with an arm's length creditor (the "Creditor") related to an aggrega...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CA7615161030
Revive Therapeutics Ltd.
RVV
LISTED
CSE
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
News Preview
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CA01559R1038
Algernon Pharmaceuticals Inc.
AGN
LISTED
CSE
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
News Preview
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces the voting results at its annual and special meeting of shareholders held earlier today (the "Meeting") including an ordinary resolution (t...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US4330001060
Hims & Hers Health Inc
HIMS
LISTED
NYSE
Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
News Preview
PHILADELPHIA, Sept. 19, 2025 /PRNewswire/ -- Berger Montague, a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholder...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US7133171055
PepGen Inc
PEPG
LISTED
NASDAQ
Kuehn Law Encourages Investors of PepGen Inc. to Contact Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of PepGen Inc. (NASDAQ: PEPG) breached their fiduciary duties to shareholders.
Ac...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US90400D1081
Ultragenyx Pharmaceutical Inc
RARE
LISTED
NASDAQ
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,561 restricted stock units of the company’s common stock to 17 newly hired non-executive...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: GB00BMVP7Y09
Royalty Pharma PLC
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
News Preview
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US55287L1017
MBX Biosciences, Inc.
MBX
LISTED
NASDAQ
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
News Preview
CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CA71719L1067
Pharmala Biotech Holdings Inc.
MDMA
LISTED
CSE
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
News Preview
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed an amended and restated preliminary sh...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: FR0004163111
Genfit SA
GNFT
LISTED
EURONEXT
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
Ac...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
Deadline Soon: RxSight, Inc. (RXST) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 22, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) securities between May 7, 2024 and July 8, 2025, inclusive (the “Class Per...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US88165K1016
Tevogen Bio Holdings Inc.
TVGN
LISTED
NASDAQ
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
News Preview
WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and rese...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Tempus AI, Inc. (NASDAQ: TEM) breached their fiduciary duties to shareholders. ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: CA98421R1055
XPhyto Therapeutics Corp.
XPHY
LISTED
CSE
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch, CEO of Power Metallic Mines Inc. (TSX-V: PNPN), will continue his role as a capital markets advisor to the Company. Mr. Lynch brings decades of early-s...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASDAQ: SMLR) between March 10, 2021 and April 15, 2025, both dates inclu...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusi...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US2825591033
89Bio, Inc.
ETNB
LISTED
NASDAQ
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Transaction in Own Shares
News Preview
For immediate release19 September 2025 WORLDWIDE HEALTHCARE TRUST PLC(the "Company") MARKET PURCHASE OF COMPANY'S OWN SHARES This notification is given, pursuant to the authority granted at an Annual General Meeting of the Company held on 9 July 2025 to make market purchases of the Company's own shares up to an aggregate maximum of 69,602,221...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US8292141053
Simulations Plus Inc
SLP
LISTED
NASDAQ
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: CA68237C1059
Onco-Innovations Limited
ONCO
LISTED
CSE
Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / Onco-Innovations Limited (CBOE CA:ONCO )(OTCQB:ONNVF )(Frankfurt:W1H) (WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to announce that Dalton Pharma Services ("Dalton") has commenced activities to manufacture Onco's proprietary nanoparticle formulation, als...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: JP3701000006
JCR Pharmaceuticals Co., Ltd.
45520
LISTED
XJPX
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
News Preview
JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has achieved a key research milestone in collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”), focused on applying JCR’s proprietary J-Brain Cargo® technology to develop a therap...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: US60770K1079
Moderna, Inc
MRNA
LISTED
NASDAQ
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
News Preview
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone advances Canada's domestic vaccine production capacity and strengthens national health security."The delivery of the first made-in-Canada mRNA va...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.09.2025
ISIN: DE0005227235
Biotest AG
BIO3
LISTED
XETR
Einberufung einer außerordentlichen Haupt-versammlung auf Verlangen der Grifols S.A.
News Preview
PRESSEMITTEILUNG
Biotest AG: Einberufung einer außerordentlichen Haupt-versammlung auf Verlangen der Grifols S.A.
Beschlussfassung über den Formwechsel in eine Kommanditgesellschaft auf Aktien (KGaA)
Dreieich, 19. September 2025. Die Biotest AG gibt bekannt, dass der Vorstand nach sorgfältiger Prüfung das am 1. August 2025 schriftlich ei......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.09.2025
ISIN: DE0005227235
Biotest AG
BIO3
LISTED
XETR
Extraordinary general meeting convened at the request of Grifols S.A.
News Preview
PRESS RELEASE
Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A.
Resolution on the change of legal form to a partnership limited by shares (KGaA)
Dreieich, 19 September 2025. Biotest AG announces that, after careful consideration, the Management Board has deemed admissible the request received in writing fro......
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US0028241000
Abbott Laboratories
ABT
LISTED
NYSE
Abbott Declares 407th Consecutive Quarterly Dividend
News Preview
ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
This marks the 407th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 17, 2025, to shareholders of record at the close of business on Oct...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
